None listed
Conditions
Interventions
Cyclophosphamide 750 mg / m2, doxorubicin 50 / m2 mg, vincristine 1.4 mg / m2 and prednisone 100 mg every 21 days are administered.
Group name:CHEMOTHERAPY MORE RADIOTERAPY Type of group
Cyclophosphamide 750 mg / m2, doxorubicin 50 / m2 mg, vincristine 1.4 mg / m2 and prednisone 100 mg every 21 days are administered. Radiotherapy includes irradiation of the entire stomach and the primary lymph nodes involved peri gastric, peri hepatic, and / or paraaortic) with high energy photons.
Sponsors
INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,
Eligibility
Inclusion criteria
Inclusion criteria: 1 Histological diagnosis of non-Hodgkin lymphoma of high grade primary gastric clinical stage I, ll1, II2, IIE, without indication of emergency surgery. 2 No evidence of other neoplasms. 3 Evidence of measurable or evaluable injuries. 4 No previous treatment. 5 Age 4,000 mm3, neutrophils> 2,000 mm3, platelets> 120,000 min3. 8 Suitable renal and hepatic function 9 Life expectancy of more than three months. 10 Geographic accessibility or treatment. 11 Written consent.
Exclusion criteria
Exclusion criteria: 1 Severe cardiomyopathy. 2 Present or past history of second neoplasia (except carcinoma in-situ of cervix and basal cell carcinoma of skin). 3 Infections or metabolic disorders not controlled. 4 More than one month between the staging and the start of treatment. 5 Previous chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:- Complete answer - answer parclal - stable inflammation - progression Measure:Evaluation of disease-free survival. Timepoints:one month | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated | — |
Countries
Peru
Outcome results
None listed